

- Sub D 2
10. (amended) The [system] kit of claim [9] 17 wherein the agent is an anti-angiogenic compound.
11. (amended) The [system] kit of claim [9] 17 wherein the agent is a procoagulant compound.
12. (amended) The [system] kit of claim [9] 17 wherein the agent is a cytokine.
13. (amended) The [system] kit of claim 12 wherein the agent is a cytokine and the cytokine is selected from the group consisting of GM-CSF, erythropoietin, thrombopoietin, G-CSF, M-CSF and SCF.
14. (amended) The [system] kit of claim [9] 17 wherein the agent is a chemotherapeutic agent.
15. (amended) The [system] kit of claim 14 wherein the agent is selected from the group consisting of alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol.
- 22 16. (amended) The system of claim 9 wherein the [device] system includes means for administering radiation to the tissue.

Please add new claims 17-23.

- Sub B 3
17. A kit for treatment of a patient to induce an immune response against transformed, infected or diseased tissue comprising:
a device for removing only components present in the blood having a molecular weight of 120,000 daltons or less and
an agent selected from the group consisting of anti-angiogenic compounds, procoagulant compounds, cytokines, chemotherapeutic agents, and radiation, in a dosage formulation for treatment of the patient.
- 10 18. The system of claim 9 wherein the device is a capillary membrane filter with a pore size of between about 0.02 and 0.05 microns.
- 11 19. The system of claim 9 wherein the device is a parallel plate filter with a pore size of between about 0.04 and 0.08 microns.
- 12 20. The system of claim 9 wherein the device comprises filters with different pore sizes or geometries to provide for staggered removal of materials from the blood.
- 13 21. The system of claim 9 wherein the device is an absorbant column selectively removing specific cytokine or cellular inhibitors from the blood.

14
22

The system of claim 9 wherein the blood is plasma.

23

The kit of claim 17 further comprising anticoagulant to treat the device for removal of components from the blood prior to use.

Remarks

The claims have been amended to more clearly distinguish the device described in applicant's earlier patent, U.S. Patent No. 4,708,713 to Lentz. This patent describes the use of a filtration device which removes substances with a molecular weight of less than 200,000. Applicant has subsequently discovered that one can provoke an immune response against a transformed or diseased tissue using a filter which removes substances of molecular weight 120,000. This is important because the process otherwise removes most of the patient's immunoglobulins, leaving him with a weakened immune system (see page 4, lines 21-23). It could not have been predicted based on Lentz that the materials being removed which resulted in remission of the tumors had a molecular weight of less than 120,000.

Claim 9 has been amended to more specifically define the filtration system *per se* and add claims 18-20 drawn to more specific embodiments. Support for the amendments to claim 9 is found at page 5, lines 15-21. Support for the new claims is found in the application at page 4, lines 12-16, and page 5, lines 6-13.

Claim 17 has been added drawn to a kit including both the filtration system and combination therapy. This claim was formerly part of claim 9. New claim 23 depends on this system and includes the anticoagulant used to initially flush the system. Support for this amendment is found at page 5, lines 26-29.